OLATEC THERAPEUTICS LLC
Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Parkinson's and Alzheimer’s disease, spinal cord injury, multiple sclerosis, type-2 diabetes, melanoma, pancreatic and breast cancers, among others. By selectively targeting NLRP3, the body’s fi... rst line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18 Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands.
OLATEC THERAPEUTICS LLC
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.olatec.com
Total Employee:
1+
Status:
Active
Contact:
833-652-8321
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
SPF Google Font API Google Analytics Apache ReCAPTCHA AJAX Libraries API GoDaddy DNS COVID-19 DigiCert SSL Google Analytics Classic
Similar Organizations
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Investors List
Milano Investment Partners SGR
Milano Investment Partners SGR investment in Series A - Olatec Therapeutics LLC
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-15 | Mustafa Noor, MD, FACP, Joins Olatec as Chief Medical Officer |
Official Site Inspections
http://www.olatec.com Semrush global rank: 5.72 M Semrush visits lastest month: 1.47 K
- Host name: pages-custom-23.weebly.com
- IP address: 199.34.228.71
- Location: San Francisco United States
- Latitude: 37.7642
- Longitude: -122.3993
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94107
More informations about "Olatec Therapeutics LLC"
Olatec - Home
Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by …See details»
Olatec Therapeutics - Crunchbase Company Profile & Funding
Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic …See details»
Olatec
OlatecSee details»
Science - Olatec
The NLRP3 protein has a tripartite domain organization containing: 1) an amino-terminal death-fold domain (pyrin domain [PYD]); 2) a central NACHT nucleotide-binding domain; and 3) …See details»
Leadership - Olatec
Ms. Skouras, a co-founder of Olatec, served as President until 2013 when she became Chairman and CEO. Ms. Skouras has over 20 years of experience in pharmaceutical drug development. …See details»
Olatec Therapeutics - Contacts, Employees, Board Members
Organization. Olatec Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of …See details»
Olatec Therapeutics LLC - VentureRadar
" Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic …See details»
Olatec Therapeutics LLC
Olatec does not undertake any obligation to update or revise the forward-looking statements contained in this Press Release to reflect events or circumstances occurring after the date this …See details»
Olatec Therapeutics Company Profile | Management and
Olatec Therapeutics Profile and History . Olatec is a clinical stage pharmaceutical company developing a new class of proprietary anti-inflammatory therapeutics to address a broad …See details»
Olatec - Company Profile - Tracxn
Nov 28, 2024 Olatec, a clinical stage pharmaceutical company, is developing a new class of proprietary anti-inflammatory therapeutics to address a broad spectrum of inflammatory …See details»
Board of Directors - Olatec
In July 2022, Craig T. Basson, MD, PhD, joined Olatec’s Board of Directors. A veteran of both large pharmaceutical and biotechnology companies, Dr. Basson served as Chief Medical …See details»
Olatec Company Profile 2024: Valuation, Funding & Investors
Olatec General Information Description. Operator of a biopharmaceutical company intended to develop novel, safe, oral, small-molecule therapeutics that target the NLRP3(nucleotide …See details»
Olatec Therapeutics - LinkedIn
Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic …See details»
Olatec Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Olatec - Products, Competitors, Financials, Employees, …
Olatec provides biopharmaceutical solutions and develops a platform of oral NLRP3 antagonist therapeutics to treat and prevent acute and chronic inflammatory diseases. Its class of …See details»
Scientific Advisory Board - Olatec
In December 2006, Curtis L. Scribner, MD, joined Olatec’s Drug Development Team and was appointed to Olatec’s Scientific Advisory Board in November 2014. Dr. Scribner has been …See details»
Olatec Therapeutics - Overview, News & Similar companies
Oct 2, 2023 Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson’s Disease with its NLRP3 Inhibitor, Dapansutrile NEW YORK--(BUSINESS WIRE)-- …See details»
Contact Us - Olatec
Olatec does not authorize other parties to use the OLT1177 trademark for their products, and will take legal action to stop other parties from mis-using OLT1177 for their products.See details»
Olatech Corp. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Olatech Corp. of Winnipeg, MB. Get the latest business insights from Dun & Bradstreet.See details»
Privacy Policy - Olatec
The purpose of this policy is to provide you with information on how Olatec Therapeutics LLC (“Olatec” or “we”) will use and protect the personally identifiable information you share with us …See details»